NASDAQ: GBT - Global Blood Therapeutics, Inc.

Yield per half year: 0%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Global Blood Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Global Blood Therapeutics, Inc.

Global Blood Therapeutics, Inc., биофармацевтическая компания, работающая на клинической стадии, занимается открытием, разработкой и предоставлением методов лечения для недостаточно обслуживаемых сообществ пациентов. Он разрабатывает свой главный кандидат на продукт, таблетки Oxbryta (вокселотор), пероральный препарат для лечения серповидно-клеточной анемии (SCD), принимаемый один раз в день. Компания оценивает Oxbryta, которая завершила клинические испытания фазы III у взрослых и подростков с SCD.

more details
Он также оценивает безопасность и фармакокинетику однократных и многократных доз Oxbryta в клинических испытаниях фазы IIa на подростках и педиатрических пациентах с SCD. Компания имеет лицензию и соглашение о сотрудничестве с Syros Pharmaceuticals, Inc. для открытия, разработки и коммерциализации методов лечения ВСС и бета-талассемии. Global Blood Therapeutics, Inc. была основана в 2011 году со штаб-квартирой в Южном Сан-Франциско, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2015-08-12
ISIN US37890U1088
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://www.gbt.com
Цена ао 67.5
Change price per day: 0% (68.49)
Change price per week: 0% (68.49)
Change price per month: 0% (68.49)
Change price per 3 month: 0% (68.49)
Change price per half year: 0% (68.49)
Change price per year: 0% (68.49)
Change price per 3 year: +166.71% (25.68)
Change price per 5 year: +26.41% (54.18)
Change price per year to date: 0% (68.49)
All parameters

Underestimation

Title Value Grade
P/S 18.8 1
P/BV 39.05 1
P/E 0 0
EV/EBITDA -1.38 0
Total: 3.63

Efficiency

Title Value Grade
ROA, % -35.64 0
ROE, % -204.89 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -2.28 10
Total: 7.8

Growth impulse

Title Value Grade
Yield Revenue, % 11085.71 10
Yield Ebitda, % 61.93 8
Yield EPS, % 44.28 6
Total: 8.2
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
27.09.2022 29.09.2022 Choi Jung
See Remarks		 Purchase 7.04 700 403 99489 0 0.15 link
27.09.2022 29.09.2022 LOVE TED W
President and CEO		 Purchase 16.4 299 972 18291 0 0.03 link
27.09.2022 29.09.2022 Habibizad Nazila
See Remarks		 Purchase 19.17 570 403 29755 0 0.05 link
27.09.2022 29.09.2022 Farrow Jeffrey S
Chief Financial Officer		 Purchase 16.4 387 909 23653 0 0.04 link
01.09.2022 06.09.2022 Farrow Jeffrey S
Chief Financial Officer		 Sale 68 2 137 990 31441 0 -0.05 link

Institutions Volume Share, %
Perceptive Advisors LLC 8305378 13.31
Janus Capital Management LLC 5776388 8.96
BlackRock Fund Advisors 5215981 8.38
Fidelity Management & Research Company LLC 3431107 5.55
Fidelity Management & Research Company LLC 2613198 4.05
Franklin Advisers, Inc. 2468534 3.83
Fidelity SelectCo, LLC 1945980 3.02
Pharmakon Advisors L.P. 1904872 2.96
Logos Global Management LP 850000 1.38
Great Point Partners LLC 595473 0.96
Fidelity Investments 381839 0.62
Hartford Funds Management Company, LLC 370098 0.59
Arctis Global LLC 293700 0.47
BNP Paribas Asset Management Luxembourg 280239 0.45
Fairmount Funds Management LLC 210000 0.34
Fernwood Investment Management, LLC 208125 0.33
Fidelity Institutional Asset Management 194559 0.3
Botty Investors LLC 188508 0.3
Nuveen Fund Advisors, LLC. 182317 0.3
John Hancock Investment Management LLC 170815 0.27
Asymmetry Capital Management, L.P. 155232 0.25
Dsc Advisors LP 135000 0.22
SATTER MANAGEMENT CO., L.P. 126270 0.2
CT Mason 126249 0.2
Security Investors, LLC 86527 0.14
Asset Management One Co., Ltd. 72045 0.12
Driehaus Capital Management LLC 61330 0.1
Fidelity Investments Canada ULC 28582 0.04
Munder Lee Investments Ltd 20405 0.03
First Trust Portfolios L.P. 13336 0.02
First Midwest Bank 9887 0.02
Gesiuris Asset Management SGIIC 9000 0.01
AMG Funds LLC 8530 0.01
AQA Capital Limited 5000 0.01
Nicholas Investment Partners 1171 0
Hennion & Walsh, Inc 500 0
Hennion & Walsh, Inc 300 0



Head Job title Payment Year of birth
Mr. Jeffrey S. Farrow CFO & Principal Accounting Officer 672.67k 1962 (63 years)
Ms. Jung E. Choi Chief Bus. & Strategy Officer 645k 1970 (55 years)
Mr. David L. Johnson Chief Commercial Officer 661.5k 1969 (56 years)
Dr. David R. Phillips Founder & Advisor N/A
Ms. Nazila Habibizad Exec. VP of Operations N/A 1963 (62 years)
Stephanie Yao Sr. Director of Corp. Communications & Investor Relations N/A
Dr. Matthew P. Jacobson Ph.D. Founder & Advisor N/A
Dr. Andrej Sali Ph.D. Founder & Advisor N/A
Dr. Ted W. Love M.D. Pres, CEO & Director 1.06M 1959 (66 years)
Dr. Kim Smith-Whitley M.D. Exec. VP and Head of R&D 654k 1961 (64 years)

Address: United States, South San Francisco, 181 Oyster Point Boulevard - open in Google maps, open in Yandex maps
Website: http://www.gbt.com